
DOC Stock Forecast & Price Target
DOC Analyst Ratings
Bulls say
Healthpeak Properties has demonstrated strong asset performance in 2023 with solid growth resulting from the easing of pandemic-related challenges. The company has achieved significant leasing success in its life science segment, with notable metrics indicating a growth trajectory that could surpass 3.0% organic growth in 2025 and 2026, while also positioning for healthy FFOPS and AFFOPS growth of 4.0%/3.4% and 5.0%/2.7% respectively. Additionally, the ongoing momentum in lab leasing and the potential recovery of its Continuing Care Retirement Community (CCRC) business to pre-COVID levels are expected to enhance overall market valuations and solidify the financial outlook for Healthpeak Properties.
Bears say
Healthpeak Properties faces a challenging outlook due to anticipated operating trend weaknesses in the life science sector, likely resulting in reduced organic growth and caution in capital deployment. Current financial metrics indicate a net debt to EBITDA ratio of 5.1x, which, while below the long-term target, reflects potential strain given expected supply pressures that could lead to increased tenant improvement costs, lower rental rates, and occupancy declines over the next year. Moreover, rising raw material and labor costs associated with development activities could further hinder investment returns and exacerbate operational disruptions within the portfolio.
This aggregate rating is based on analysts' research of Healthpeak Properties Inc and is not a guaranteed prediction by Public.com or investment advice.
DOC Analyst Forecast & Price Prediction
Start investing in DOC
Order type
Buy in
Order amount
Est. shares
0 shares